After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ACAD belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $4.52B. A total of 1.03 million shares were traded on the day, compared to an average of 1.69M shares.
In the most recent transaction, Schneyer Mark C. sold 10,262 shares of ACAD for 23.69 per share on Nov 18 ’25. After the transaction, the EVP, CHIEF FINANCIAL OFFICER now owns 53,338 company shares. In a previous transaction on Nov 18 ’25, Kihara James sold 4,084 shares at 23.69 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 25,058.
Among the insiders who sold shares, Daly James M disposed of 30,000 shares on Nov 10 ’25 at a per-share price of $22.37. This resulted in the Director holding 4,041 shares of ACAD after the transaction. In another insider transaction, James M Daly bought 30,000 shares at $22.37 per share on Nov 10 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ACAD has a high of $28.35 and a low of $13.40.
As of this writing, ACAD has an earnings estimate of $0.14 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $0.23 per share and a lower estimate of -$0.03. The company reported an EPS of $0.86 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $5.42, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.05.
